Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Lichen Planopilaris and Frontal Fibrosing Alopecia
Description
The presentation discusses Lichen Planopilaris (LPP) and Frontal Fibrosing Alopecia (FFA), focusing on clinical characteristics, diagnosis, and treatment approaches. LPP is identified as a primary lymphocytic scarring alopecia, typically affecting women aged 40 to 70, manifesting as irregular patches of hair loss with associated erythema and scale. It has various clinical forms, including Graham Little Picardie syndrome, and raises questions regarding its relation to FFA. The latter is characterized as a hair emergency due to its impact on the frontal hairline, predominantly in postmenopausal Caucasian females, though cases in Black patients are increasingly recognized. The presentation emphasizes the importance of accurate diagnosis to avoid mislabeling hair loss as traction alopecia and underscores the necessity of thorough examinations, including biopsies and trichoscopy. Treatment options include topical steroids, intralesional injections, and systemic therapies like hydroxychloroquine and finasteride, although there is no FDA-approved treatment for either condition. Emerging therapies, such as JAK inhibitors, show promise, marking the future of treatment for LPP and FFA. The session highlights the need for greater awareness of these conditions across diverse populations and stresses the complexity in their clinical manifestations.
View moreConclusions
- Lichen planopilaris (LPP) and frontal fibrosing alopecia (FFA) are primarily lymphocytic cicatricial alopecias that predominantly affect Caucasian females between the ages of 40-70.
- FFA is termed a hair emergency due to the permanent scarring it causes along the frontal hairline.
- FFA presentations can vary in black patients and may present without classic symptoms such as redness or visible scale.
- Misdiagnosis of FFA in black patients may lead to mistaken diagnoses for traction alopecia or other forms of hair loss incidents.
- Both LPP and FFA can occur in diverse populations, not limited to traditionally identified groups.
- Dermoscopy findings in black patients with LPP and FFA can differ significantly from classical presentations, complicating diagnosis.
- Genetic predispositions and potential triggers for both conditions include viral infections, contact allergens, and hormonal influences, among others.
- Treatment for LPP and FFA includes topical steroids, calcineurin inhibitors, and systemic therapies, with varying degrees of success reported in the literature.
- Emerging therapies such as oral minoxidil, tofacitinib, and baricitinib show promise but require further study for definitive conclusions.
- Future strategies in the treatment of LPP and FFA need to address the specific presentations and underlying mechanisms in patients of all backgrounds, especially black patients.
- Kang et al. Dermatol Ther. 2008 Jul-Aug;21(4):249-56.
- Svigos K. et al. Am J Clin Dermatol. 2021 Sep;22(5):681-692.
- N.C. Dlova, H.F. Jordaan, A. Skenjane, N. Khoza, A. Tosti. Frontal fibrosing alopecia: a clinical review of 20 black patients from South Africa. British Journal of Dermatology, Volume 169, Issue 4, 1 October 2013, Pages 939-941, https://doi.org/10.1111/bjd.12424.
- P. Adotama, V. Callender, A. Kolla, C. Young, P. Jones, K. Svigos, L. Yin, N. Ugonabo, Laura N. Uwakwe MD, Leah A. Cardwell MD, Emily H. Dothard MD, Bernice I. Baroudi BS, and Amy J. McMichael MD. Frontal Fibrosing Alopecia and Concomitant Lichen Planus Pigmentosus: A Case Series of Seven African American Women. British Journal of Dermatology, Volume 185, Issue 5, 1 November 2021, Pages 1074-1076.
- Ho and Shapiro. J Am Acad Dermatol. 2019 Aug;81(2):568-580.
- Heppet et al. Facial Plast Surg. 2018 Feb;34(1):88-94.
- Strazzulla et al. J Am Acad Dermatol. 2018 Jan;78(1):203-205.
- Preda-Naumescu A, et al. J Drugs Dermatol. 2021 Jul 1;20(7):779-782.
- Jacob Griggs 1, Ralph M Trüeb 2, Maria Fernanda Reis Gavazzoni Dias 3, Maria Hordinsky 4, Antonella Tosti 5. J Am Acad Dermatol. 2021 Dec;85(6):1557-1564. doi: 10.1016/j.jaad.2019.12.056.
- Sergio Vañó-Galván 1, Lara Trindade de Carvalho 2, David Saceda-Corralo 3, Rita Rodrigues-Barata 3, Karolina L Kerkemeyer 2, Rodney D Sinclair 2, Ánaela Hermosa-Gelbard 3, Óscar M Moreno-Arrones 3, Juan Jimenez-Cauhe 4, Bevin Bhovrul 2. J Am Acad Dermatol. 2022 Sep;87(3):663-666. doi: 10.1016/j.jaad.2022.02.027.